Medi-Scan Inc. has emerged from stealth mode with cloud-based software that converts the data on ultrasound analog 2D grayscale images into a digital 3D high-definition (HD) format in less than two minutes. The company is currently focusing its efforts on the heart and lungs, with the aim of providing quick, point-of-service evaluation and triaging of patients with heart disease and other conditions, including COVID-19.

TORONTO – Novel. Unique. Revolutionary. Terms too often used to indiscriminately describe medical devices that have yet to prove their stuff. Not so at France’s Ministry of Health which takes care to deem winning devices under its Forfait Innovation (FI) program “truly innovative, not simply incremental developments.” Last week the FI awarded Vancouver, British Columbia’s Evasc Neurovascular Inc. €2.76 million (US$3.37 million) to test its CE-marked Eclips for treating intracranial bifurcation aneurysms during a 119-patient trial at 20 French sites in 2021.

Bionaut Labs emerged from five years in stealth mode raising $20 million to develop Bionauts, microrobots designed to deliver therapies to treat brain disorders. The financing will support the company’s therapeutic program in glioma through preclinical development and further research and development in Huntington’s disease.

Bionaut Labs emerged from five years in stealth mode raising $20 million to develop Bionauts, microrobots designed to deliver therapies to treat brain disorders. The financing will support the company’s therapeutic program in glioma through preclinical development and further research and development in Huntington’s disease. Khosla Ventures led the financing with participation by Upfront Ventures, Revolution LLC, BOLD Capital Partners, and Compound.

If Marvel’s Peter Parker had chosen to apply his graduate work in biochemistry and his web-shooters to medicine, he might have created something like Nanomedic Technologies Ltd.’s Spincare system. The system uses a hand-held medical gun that prints a flexible, transparent layer of artificial skin directly on a wound or burn. The Electrospun Healing Fiber (EHF) technology creates a waterproof, protective nano polymer matrix.

RNA has “huge potential” as a therapeutic modality and is beginning to deliver on that potential. But “manufacturing RNA has issues in production, delivery and performance,” Thomas Barnes told BioWorld. Barnes is the CEO of startup Orna Therapeutics LLC, which has the goal of addressing those issues with oRNA, an engineered form of circular RNA.

Asalyxa Bio Inc. has closed on an oversubscribed seed financing of more than $2 million designed to advance its lead candidate, ASX-100, into the clinic in acute respiratory distress syndrome.

PERTH, Australia – About seven years ago, Australia’s George Institute for Global Health conducted a study to find out how many people require dialysis for end-stage kidney failure compared to how many people receive treatment.

CAJICA, Colombia – China’s Anticancer Bioscience, a company focused on developing precision oncology medicines, has raised ¥66 million (US$10.2 million) to expand its small-molecule and natural product screening libraries and move two programs into IND-enabling studies.

CAJICA, Colombia – China’s Anticancer Bioscience, a company focused on developing precision oncology medicines, has raised ¥66 million (US$10.2 million) to expand its small-molecule and natural product screening libraries and move two programs into IND-enabling studies.